{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li LX"],"funding":["Cancer Council South Australia","National Health and Medical Research Council"],"pagination":["379"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10964615"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(1)"],"pubmed_abstract":["<h4>Background</h4>Multiple studies have indicated that patients with high body mass index (BMI) may have favourable survival outcomes following treatment with an immune checkpoint inhibitor (ICI). However, this evidence is limited by several factors, notably the minimal evidence from randomised controlled trials (RCTs), the use of categorised BMI with inconsistent cut point definitions, and minimal investigation of contemporary combination ICI therapy. Moreover, whether overweight and obese patients gain a larger benefit from contemporary frontline chemoimmunotherapy in non-small cell lung cancer (NSCLC) is unclear.<h4>Methods</h4>This secondary analysis pooled individual patient data from the intention-to-treat population of the IMpower130 and IMpower150 RCTs comparing chemoimmunotherapy"],"journal":["BMC cancer"],"pubmed_title":["A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials."],"pmcid":["PMC10964615"],"funding_grant_id":["GNT2013565","APP2008119"],"pubmed_authors":["Li LX","Socinski MA","Karapetis CS","Hopkins AM","Shahnam A","McKinnon RA","Kichenadasse G","Sorich MJ","Rowland A"],"additional_accession":[]},"is_claimable":false,"name":"A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials.","description":"<h4>Background</h4>Multiple studies have indicated that patients with high body mass index (BMI) may have favourable survival outcomes following treatment with an immune checkpoint inhibitor (ICI). However, this evidence is limited by several factors, notably the minimal evidence from randomised controlled trials (RCTs), the use of categorised BMI with inconsistent cut point definitions, and minimal investigation of contemporary combination ICI therapy. Moreover, whether overweight and obese patients gain a larger benefit from contemporary frontline chemoimmunotherapy in non-small cell lung cancer (NSCLC) is unclear.<h4>Methods</h4>This secondary analysis pooled individual patient data from the intention-to-treat population of the IMpower130 and IMpower150 RCTs comparing chemoimmunotherapy","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-07-16T14:56:36.921Z","creation":"2026-07-09T11:02:40.194Z"},"accession":"S-EPMC10964615","cross_references":{"pubmed":["38528478"],"doi":["10.1186/s12885-024-12132-w"]}}